EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Dividend confirmation
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that the Board has confirmed a cash dividend of 1.1p per ordinary share which will be paid on 1 December 2021.
The dividend timetable dates are below:
|
Ex-dividend date: |
4 November 2021 |
|
Record date: |
5 November 2021 |
|
Payment date: |
1 December 2021 |
|
EKF Diagnostics Holdings plc |
|||
|
Christopher Mills, Non-executive Chairman |
Tel: +44 (0)29 2071 0570 |
||
|
Mike Salter, CEO |
|
||
|
Richard Evans, FD & COO |
|
||
|
|
|
||
|
Singer Capital Markets (Nominated Adviser & Joint Broker) |
Tel: +44 (0)20 7496 3000 |
||
|
Aubrey Powell / George Tzimas / Tom Salvesen |
|
||
|
|
|
||
|
Investec Bank plc (Joint Broker) |
Tel: +44 (0)20 7597 4000 |
||
|
Gary Clarence / Daniel Adams |
|
||
|
|
|
||
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
||
|
Paul McManus / Lianne Applegarth |
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
||
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.
EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the across sites in the US, UK and Europe for a variety of life science products. Demand for contract manufacturing of COVID-19 sample collection tests and kits has grown dramatically during the pandemic, however the capabilities can be applied to other areas of diagnostic testing, molecular disease and forensic test manufacture.